Endo Completes International Pharmaceuticals Business Divestiture
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Should l Buy ?
Source: PRnewswire
Endo's Business Divestiture: Endo, Inc. has completed the sale of its International Pharmaceuticals business to Knight Therapeutics Inc. for a total cash consideration of up to approximately $105 million.
Forward-Looking Statements Caution: The press release includes forward-looking statements regarding future expectations and results, highlighting potential risks and uncertainties that could affect actual outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
